An FDA panel will hold a meeting beginning Thursday to discuss whether to reclassify electroshock devices, which are used to treat major depression, from the high-risk category to medium-risk. The FDA review comes amid calls from specialists and psychiatric groups, including the American Psychiatric Association, for the downgraded device designation.

Related Summaries